Cargando…

Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy

BACKGROUND: Anti-PD-1 immunotherapies have shown clinical benefit in multiple cancers, but response was only observed in a subset of patients. Predicting which patients will respond is an urgent clinical need, but current companion diagnosis based on PD-L1 IHC staining shows limited predictability....

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Can, He, Hua, Li, Xiaobing, Su, Maureen A., Cao, Yanguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353899/ https://www.ncbi.nlm.nih.gov/pubmed/30587849 http://dx.doi.org/10.1038/s41416-018-0363-8

Ejemplares similares

Correction: Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy
por: Liu, Can, et al.
Publicado: (2019)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy
por: Amato, Carol M., et al.
Publicado: (2020)

FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
por: Flaus, A., et al.
Publicado: (2021)

Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients
por: Mirjačić Martinović, Katarina, et al.
Publicado: (2023)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer
por: He, Yinjun, et al.
Publicado: (2023)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association
por: Wu, Chia-Chin, et al.
Publicado: (2022)

Exploring the Potential Use of a PBMC-Based Functional Assay to Identify Predictive Biomarkers for Anti-PD-1 Immunotherapy
por: Bacot, Silvia M., et al.
Publicado: (2020)

Phospho-STAT1 expression as a potential biomarker for anti-PD-1/anti-PD-L1 immunotherapy for breast cancer
por: Nakayama, Yuko, et al.
Publicado: (2019)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Screening biomarkers for predicting the efficacy of immunotherapy in patients with PD-L1 overexpression
por: Zhu, Xiaodan, et al.
Publicado: (2023)

Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies
por: Kambayashi, Yumi, et al.
Publicado: (2019)

Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
por: Wang, Tao, et al.
Publicado: (2022)

Granzyme family acts as a predict biomarker in cutaneous melanoma and indicates more benefit from anti-PD-1 immunotherapy
por: Wu, Xia, et al.
Publicado: (2021)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy
por: Luo, Linfeng, et al.
Publicado: (2023)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance
por: Liu, Can, et al.
Publicado: (2023)

Decoding the Complexity of Immune–Cancer Cell Interactions: Empowering the Future of Cancer Immunotherapy
por: Maffuid, Kaitlyn, et al.
Publicado: (2023)

SLAMF8 expression predicts the efficacy of anti‐PD1 immunotherapy in gastrointestinal cancers
por: Zhang, Qun, et al.
Publicado: (2021)

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
por: Hughes, Jing, et al.
Publicado: (2015)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
por: Bulen, Benjamin J., et al.
Publicado: (2023)

New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities
por: Dai, Mengyuan, et al.
Publicado: (2022)

DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
por: Zhu, Zhongling, et al.
Publicado: (2018)

Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood
por: Rad Pour, Soudabeh, et al.
Publicado: (2021)

Low-intensity focused ultrasound targeted microbubble destruction reduces tumor blood supply and sensitizes anti-PD-L1 immunotherapy
por: Wu, Nianhong, et al.
Publicado: (2023)

Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities
por: Dai, Mengyuan, et al.
Publicado: (2022)

scCURE identifies cell types responding to immunotherapy and enables outcome prediction
por: Zou, Xin, et al.
Publicado: (2023)

Case report: A colorectal cancer patient with microsatellite instability-high and MSH2 germline mutation failed to respond to anti-PD-1 immunotherapy
por: Zhang, Qun, et al.
Publicado: (2022)

Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer
por: Cheng, Guoping, et al.
Publicado: (2022)

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
por: Brogden, Kim A., et al.
Publicado: (2018)

A multispecies framework for modeling adaptive immunity and immunotherapy in cancer
por: Qi, Timothy, et al.
Publicado: (2023)

CD36-BATF2\MYB Axis Predicts Anti-PD-1 Immunotherapy Response in Gastric Cancer
por: Jiang, Qiuyu, et al.
Publicado: (2023)

DLL3 Is a Prognostic and Potentially Predictive Biomarker for Immunotherapy Linked to PD/PD-L Axis and NOTCH1 in Pancreatic Cancer
por: Lacalle-Gonzalez, Carlos, et al.
Publicado: (2023)

An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
por: Cowles, Sarah C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ss3fqvi0g085l5fcjtp750qvmq